January 20th 2025
The novel therapeutic demonstrated a strong safety profile and showed efficacy in reducing symptoms during the early stages of treatment.
January 13th 2025
FDA Approves GSK Vaccine Arexvy for Prevention of RSV in High-Risk Adults Aged 50 to 59 Years
June 7th 2024GSK announced today approval by the US FDA of a label expansion for the adjuvanted RSV vaccine that adds adults aged 50 to 59 years who are at elevated risk for RSV disease to the vaccine’s current indication.